Pricing
  1. JP-listed companies
  3. Financials
  4. Cash from investing

(4586)

Market cap
¥6.6B
P/E ratio
Medrex develops new pharmaceuticals using proprietary skin-patch delivery technology that improves drug effectiveness and reduces side effects.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from investing (Million JPY)YoY (%)
Dec 31, 2025-83+2522.88%
Dec 31, 2024-3+315.68%
Dec 31, 2023-1-61.24%
Dec 31, 2022-2-22.97%
Dec 31, 2021-3-50.14%
Dec 31, 2020-5-97.98%
Dec 31, 2019-252-144.38%
Dec 31, 2018569-185.95%
Dec 31, 2017-661-261.34%
Dec 31, 2016410-1039.50%
Dec 31, 2015-44-63.58%
Dec 31, 2014-120

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat